PALB2 mutations were also associated with a high-risk of breast cancer (OR = 6.95, 95% CI 3.71–12.70), consistent with prior data.14 Our results support the rarity of CDH1, PTEN, and STK11 mutations in FBC cohorts and the classification of TP53 and PALB2 as high risk genes (OR > 5) for FBC. This evidence concerns the gene TP53 and breast cancer.